FDA approves biosimilar of Amgen’s Enbrel
The U.S. Food and Drug Administration formally approved a competing biosimilar of Amgen’s top-selling drug Enbrel on Aug. 30. Made by Switzerland-based Novartis, Erelzi mimics the effects of Enbrel. Enbrel, which was first approved in 1998, is approved to treat rheumatoid arthritis and other conditions by decreasing the amount of a protein produced by the Read More →
Read More →Amgen reports positive results for Prolia
Thousand Oaks-based biotech giant Amgen announced positive results from patients receiving Prolia to treat inflammation Aug. 29. In the study, Prolia, normally used to treat osteoporosis, hypercalcemia and bone cancer, was used to treat inflammation. The two-year study enrolled 795 patients to evaluate the safety of two 60 milligram doses of Prolia given under the Read More →
Read More →
Amgen alumni start their own biotech companies
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Dubroff: Great retail guessing game puts a Macy’s store in the spotlight
It seems crazy to write about Christmas in August. But as the shopping season starts earlier and earlier, there’s more and more trouble brewing for retailers. News that Macy’s is closing another 100 stores — after announcing 36 exits earlier this year — got raves from Wall Street as the nation’s flagship chain battles online Read More →
Read More →Ventura County SCORE chapter assists Hispanic entrepreneurs
A group of regional mentors is trying to make more opportunities available to Hispanic entrepreneurs. Formerly the Service Corps of Retired Executives, the SCORE Association has 348 chapters throughout the U.S. Today, the Ventura County chapter has about 40 volunteers and two of them said not enough services are offered to Hispanic entrepreneurs for a Read More →
Read More →Inphi’s second quarter revenues soar
Inphi saw revenues rise during the second quarter as it sold off its memory products business. On June 30, Inphi announced it would sell its memory products business to Sunnyvale-based Rambus. Inphi said revenues rose from $49.4 million in 2015 to $60.5 million during the second quarter of 2016 when revenues from the memory business Read More →
Read More →Abbvie sues Amgen to block sales of Humira biosimilar
Thousand Oaks-based biotech giant Amgen faces a lawsuit seeking to block it from selling a biosimilar of AbbVie’s popular Humira. The rheumatoid arthritis medicine is Abbvie’s best seller. Sales were up 17 percent in the second quarter to $4.15 billion and accounted for 61 percent of AbbVie’s 2015 revenue. Abbvie claims Amgen’s proposed copy would Read More →
Read More →
SPONSORED CONTENT:
